PLSM (PLSM)

PLSM (PLSM) Healthcare & Pipeline Overview

Pulsenmore Ltd. (PLSM) is a pioneering Israeli company in the healthcare sector, focused on self-scan ultrasound technology that enables remote clinical diagnosis, enhancing patient accessibility and healthcare efficiency across Israel and Europe.

What Is the Investment Thesis for PLSM?

Pulsenmore Ltd. presents a unique investment thesis characterized by its innovative self-scan ultrasound technology, which addresses the increasing demand for remote healthcare solutions. The company currently holds a market capitalization of approximately $38 million, with a gross margin of 84.2%, indicating strong potential for profitability if operational efficiencies can be achieved. However, the company is currently facing significant challenges, including a negative profit margin of -39.6%, which underscores the importance of scaling operations and increasing market adoption of its products. Key growth catalysts include expanding its product offerings and geographic reach, particularly within Europe, where the demand for remote diagnostics is surging. The potential for partnerships with healthcare providers and integration into existing healthcare systems could further enhance revenue streams. Investors should also consider the risks associated with regulatory approvals and market competition, which could impact the company’s growth trajectory over the next few years.

Based on FMP financials and quantitative analysis

PLSM Key Highlights

• Market capitalization of approximately $38 million, reflecting the company's current valuation in the medical device sector.
• Gross margin of 84.2%, indicating strong potential for profitability as the company scales its operations.
• Negative profit margin of -39.6%, highlighting the need for operational improvements and revenue growth.
• Beta of 0.37, suggesting lower volatility compared to the overall market, which may appeal to risk-averse investors.
• No dividend yield, as the company is focused on reinvesting in growth and innovation.

Who Are PLSM's Competitors?

PLSM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PLSM's Key Strengths?

• Innovative product offering that addresses a growing market need.
• Strong gross margins indicating potential for profitability.
• Experienced leadership team with a focus on healthcare innovation.

What Are PLSM's Weaknesses?

• Negative profit margin indicating current operational challenges.
• Limited market presence outside of Israel and Europe.
• Dependence on a single product line for revenue generation.

What Could Drive PLSM Stock Higher?

• Expansion into European markets to capture growing demand for remote diagnostics.
• Development of partnerships with telehealth providers to enhance service offerings.
• Regulatory approvals for new product features to increase market competitiveness.

What Are the Key Risks for PLSM?

• Financial-distress signal — its Altman Z-Score of 0.19 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-40.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles that may delay product approvals and market entry.
• Competition from established medical device companies with larger market shares.
• Economic downturns that could impact healthcare spending and investment.

What Are the Growth Opportunities for PLSM?

• Expansion into European markets: Pulsenmore aims to penetrate the European healthcare market, which is experiencing a shift towards remote diagnostics. The European ultrasound market is expected to reach $1.5 billion by 2028, providing a substantial growth opportunity for Pulsenmore's self-scan technology. By establishing partnerships with healthcare providers and leveraging existing distribution channels, the company can enhance its market presence and drive revenue growth over the next 3-5 years.
• Development of additional product features: Enhancing the functionality of the Pulsenmore home ultrasound system by integrating advanced features such as AI-driven diagnostics could significantly increase its value proposition. The global AI in healthcare market is projected to grow to $45.2 billion by 2026, representing a lucrative opportunity for Pulsenmore to differentiate its product and attract a broader customer base.
• Partnerships with telehealth platforms: Collaborating with telehealth providers can facilitate the integration of Pulsenmore's ultrasound technology into remote patient monitoring systems. As the telehealth market continues to expand, projected to reach $459.8 billion by 2030, such partnerships could drive adoption and increase the utilization of Pulsenmore's devices in clinical settings.
• Regulatory approvals and certifications: Achieving regulatory approvals from key health authorities in new markets can unlock significant growth potential. Obtaining CE marking and FDA clearance for its devices would enable Pulsenmore to market its products more broadly, tapping into larger patient populations and enhancing its credibility within the healthcare sector.
• Increased awareness and adoption of remote diagnostics: As healthcare systems worldwide continue to adapt to the challenges posed by the COVID-19 pandemic, the demand for remote diagnostic solutions is expected to rise. Pulsenmore's innovative technology aligns with this trend, positioning the company to capitalize on the growing acceptance of home-based healthcare solutions in the coming years.

What Opportunities Does PLSM Have?

• Expansion into new geographic markets with high demand for remote diagnostics.
• Partnerships with telehealth providers to enhance service offerings.
• Development of additional features to increase product value.

What Threats Does PLSM Face?

• Intense competition from established medical device companies.
• Regulatory hurdles that may delay product approvals.
• Market volatility affecting investment and operational funding.

What Are PLSM's Competitive Advantages?

• Innovative self-scan technology that empowers patients and reduces healthcare costs.
• Strong gross margin of 84.2%, indicating efficient operations and potential for profitability.
• Focus on remote diagnostics aligns with current healthcare trends towards decentralization.

What Does PLSM Do?

Founded in 2014 and headquartered in Omer, Israel, Pulsenmore Ltd. is at the forefront of medical technology innovation, specifically in the field of ultrasound diagnostics. The company specializes in developing self-scan ultrasound devices that empower patients to conduct their own scans from the comfort of their homes, thereby facilitating remote clinical diagnosis and screening. The flagship product, the Pulsenmore home ultrasound system, integrates a handheld ultrasound cradle that connects with the patient’s smartphone, allowing for seamless image capture and transmission. This system is complemented by a mobile app that uploads images to the cloud, enabling healthcare professionals to review scans in real-time or at their convenience via a clinician dashboard. This innovative approach not only enhances patient engagement but also aims to reduce the burden on healthcare facilities by decentralizing diagnostic processes. With a dedicated team of 58 employees, Pulsenmore is strategically positioned to expand its market presence in both Israel and Europe, targeting a growing demand for remote healthcare solutions. The company’s commitment to improving healthcare accessibility is reflected in its technology, which is designed to meet the evolving needs of patients and clinicians alike, ultimately contributing to better health outcomes.

What Products and Services Does PLSM Offer?

• Develops self-scan ultrasound devices for remote clinical diagnosis.
• Offers a home ultrasound system that connects with patients' smartphones.
• Provides a mobile app for uploading ultrasound images to the cloud.
• Facilitates real-time clinician access to patient scans via a dashboard.
• Focuses on enhancing healthcare accessibility and efficiency.
• Operates primarily in Israel and Europe.

How Does PLSM Make Money?

• Generates revenue through the sale of self-scan ultrasound devices.
• Offers subscription-based services for cloud storage and data management.
• Potential partnerships with healthcare providers for integrated services.
• Focuses on expanding product offerings to include additional diagnostic tools.

What Industry Does PLSM Operate In?

The medical devices industry is experiencing significant growth, driven by technological advancements and an increasing focus on remote healthcare solutions. The global market for ultrasound devices is projected to grow at a CAGR of approximately 5.5% from 2021 to 2028, fueled by rising demand for non-invasive diagnostic tools. Pulsenmore Ltd. operates within this expanding landscape, positioning itself as a leader in self-scan ultrasound technology. The competitive landscape includes established players and emerging startups, but Pulsenmore's focus on remote diagnostics differentiates it from traditional ultrasound providers, catering to a growing segment of patients seeking convenient healthcare solutions.

Who Are PLSM's Key Customers?

• Healthcare providers seeking innovative diagnostic solutions.
• Patients looking for convenient and accessible ultrasound services.
• Telehealth platforms integrating remote diagnostic tools into their services.

Company Profile

PLSM operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Omer, IL. The company is led by CEO Elazar Sonnenschein. PLSM has traded publicly since 2026.

PLSM (PLSM) Valuation Context

Valued at $32.25M, PLSM is classified as a micro-cap stock. Relative to its peer group, PLSM's quantitative score of 60/100 is roughly in line with the peer average of 68/100.

ROE -41%Key Financial Metrics

Return on equity for PLSM stands at -40.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -31.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -47.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -35.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

PLSM's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.19 places it in the distress zone, a signal of elevated financial risk.

PLSM Financials

PLSM Latest News

PLSM Analyst Consensus

PLSM MoonshotScore

Common Questions About PLSM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources